In:
The Korean Journal of Internal Medicine, Korean Association of Internal Medicine, Vol. 38, No. 4 ( 2023-07-01), p. 493-503
Abstract:
Background/Aims: Tegoprazan, a novel potassium-competitive acid blocker, has shown rapid action and gastric acid inhibition. In this study, we evaluated the efficacy of a tegoprazan-based, nonbismuth-containing quadruple (concomitant) therapy for the primary eradication of 〈 i 〉 Helicobacter pylori 〈 /i 〉 .Methods: We conducted a prospective, single-arm, single-center, primitive study to verify the efficacy of a 10-day tegoprazan- based (50-mg dose) concomitant therapy, including amoxicillin (1,000-mg dose), clarithromycin (CLA; 500-mg dose), and metronidazole (MET; 500-mg dose) twice daily as a first-line treatment for 〈 i 〉 H. pylori 〈 /i 〉 eradication.Results: We tested consecutive cultures for antibiotic susceptibility and minimum inhibitory concentrations. We enrolled 84 participants; 79 (94.0%) completed first-line therapy. The overall intention-to-treat and per-protocol eradication rates were 90.5% (95% confidence interval [CI], 82.1−95.8) and 96.2% (95% CI, 83.4–97.6), respectively. Of the 73 participants evaluated for antibiotic resistance, 19 (26.0%), 32 (42.5%), and 8 (11.0%) exhibited CLA, MET, and CLA and MET dual resistance, respectively. Of these, 39 participants (66.1%) exhibited successful eradication after the therapeutic regimen despite antibiotic resistance.Conclusions: The 10-day tegoprazan-based concomitant therapy may be an effective first-line treatment for eradicating 〈 i 〉 H. pylori 〈 /i 〉 .
Type of Medium:
Online Resource
ISSN:
1226-3303
,
2005-6648
DOI:
10.3904/kjim.2022.345
Language:
English
Publisher:
Korean Association of Internal Medicine
Publication Date:
2023
detail.hit.zdb_id:
2500508-X
Permalink